Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Income from Continuing Operations came in at 288249000.0 in Q1 2026, down 365.36% YoY from 108625401.14 in Q1 2025, and down 99.04% on a QoQ basis from 144821000.0 in Q4 2025.
Powered by 
Analysis
Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Income from Continuing Operations data on file, last reported at 288249000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 365.36% year-over-year to 288249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 607006000.0 (down 198.13% YoY) and the FY2025 annual result came in at 62919000.0, up 6292000.0% from the prior year.
- Income from Continuing Operations declined to 288249000.0 in Q1 2026, from 144821000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 17651000.0 in Q1 2022 to a low of 288249000.0 in Q1 2026.
- A 5-year average of 62771352.94 and a median of 38561000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations climbed 24.19% — and 2026, when it plunged 365.36%.
- Tracing VERA's Income from Continuing Operations over 5 years: stood at 33246000.0 in 2022, then retreated by 15.99% to 38561000.0 in 2023, then retreated by 14.42% to 44122000.0 in 2024, then sank by 228.23% to 144821000.0 in 2025, then slumped by 99.04% to 288249000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 288249000.0 (Q1 2026), 144821000.0 (Q4 2025), and 81420000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vera Therapeutics | 2.61 Bn | 2.61 Bn | - | -108.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -108.99 Mn |
| Mar 31, 2026 | -120.60 Mn |
| Dec 31, 2025 | -90.59 Mn |
| Sep 30, 2025 | -80.16 Mn |
| Jun 30, 2025 | -75.70 Mn |
| Mar 31, 2025 | -52.08 Mn |
| Dec 31, 2024 | -44.12 Mn |
| Sep 30, 2024 | -46.98 Mn |
| Jun 30, 2024 | -34.15 Mn |
| Mar 31, 2024 | -28.83 Mn |
| Dec 31, 2023 | -26.12 Mn |
| Sep 30, 2023 | -20.54 Mn |
| Jun 30, 2023 | -20.65 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | -33.29 Mn |
| Sep 30, 2022 | -24.82 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | -17.11 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |